[go: up one dir, main page]

WO2003031435A8 - Derives pyrazole inhibiteurs de transport de glycine - Google Patents

Derives pyrazole inhibiteurs de transport de glycine

Info

Publication number
WO2003031435A8
WO2003031435A8 PCT/EP2002/010172 EP0210172W WO03031435A8 WO 2003031435 A8 WO2003031435 A8 WO 2003031435A8 EP 0210172 W EP0210172 W EP 0210172W WO 03031435 A8 WO03031435 A8 WO 03031435A8
Authority
WO
WIPO (PCT)
Prior art keywords
disease
transporter inhibitors
glycine transporter
pyrazole derivatives
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/010172
Other languages
English (en)
Other versions
WO2003031435A1 (fr
Inventor
Kai Schiemann
Michael Arlt
Dirk Finsinger
Karl-August Ackermann
Wilfried Rautenberg
Joachim Leibrock
Hartmut Greiner
Takahiko Tobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Merck Patent GmbH
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Yamanouchi Pharmaceutical Co Ltd filed Critical Merck Patent GmbH
Priority to AU2002342675A priority Critical patent/AU2002342675A1/en
Publication of WO2003031435A1 publication Critical patent/WO2003031435A1/fr
Publication of WO2003031435A8 publication Critical patent/WO2003031435A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), ainsi que des sels et des solvates de ces composés, dans laquelle X, R?1, R2, R3, R4 et R5¿ sont tels que définis dans la revendication 1. Ces composés sont des inhibiteurs du transport de la glycine et peuvent être utilisés en médecine humaine et vétérinaire pour la prophylaxie et le traitement dans les cas de schizophrénie, dépression, démence, maladie de Parkinson, maladie d'Alzheimer, démence du corps de Lewy, maladie de Huntington, syndrome de Tourette, anxiété, restrictions d'apprentissage et de mémoire, maladies neurodégénératives et d'autres troubles cognitifs, ainsi que dans les cas de douleurs et de dépendance à la nicotine.
PCT/EP2002/010172 2001-10-06 2002-09-11 Derives pyrazole inhibiteurs de transport de glycine Ceased WO2003031435A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002342675A AU2002342675A1 (en) 2001-10-06 2002-09-11 Pyrazole derivatives as glycine transporter inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10149370.3 2001-10-06
DE10149370A DE10149370A1 (de) 2001-10-06 2001-10-06 Pyrazolderivate

Publications (2)

Publication Number Publication Date
WO2003031435A1 WO2003031435A1 (fr) 2003-04-17
WO2003031435A8 true WO2003031435A8 (fr) 2003-05-15

Family

ID=7701652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010172 Ceased WO2003031435A1 (fr) 2001-10-06 2002-09-11 Derives pyrazole inhibiteurs de transport de glycine

Country Status (3)

Country Link
AU (1) AU2002342675A1 (fr)
DE (1) DE10149370A1 (fr)
WO (1) WO2003031435A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037793A1 (fr) * 2002-10-24 2004-05-06 Wakamoto Pharmaceutical Co., Ltd. Derives pyrazole-4-alcanoate inhibant la cyclo-oxygenase et la 5-lipoxygenase
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315572A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315569A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
MX2007008460A (es) * 2005-01-14 2007-07-25 Organon Nv Inhibidores de la reabsorcion de glicina para el tratamiento de dependencia a farmacos.
CA2624338C (fr) 2005-10-05 2016-09-13 Bayer Cropscience Ag Vegetaux possedant un contenu accru de sucres amino
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
WO2007052615A1 (fr) 2005-10-31 2007-05-10 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un hétérocycle et fongicide contenant celui-ci
EP1971595B1 (fr) * 2005-12-30 2013-10-16 Merck Sharp & Dohme Corp. Inhibiteurs de cetp
NZ573129A (en) * 2006-06-28 2011-06-30 Amgen Inc Piperazine acetic acid glycine transporter-1 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CN102702185A (zh) 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
JP5298129B2 (ja) 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化因子
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CN102083797B (zh) 2008-04-01 2014-06-04 Abbvie公司 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2010099054A2 (fr) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
JP5722891B2 (ja) 2010-07-15 2015-05-27 大日本住友製薬株式会社 ピラゾール化合物
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2970131B1 (fr) 2013-03-14 2017-11-15 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
MX382991B (es) 2013-03-14 2025-03-13 Epizyme Inc Inhibidores de la arginina metiltransferasa y usos de los mismos.
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (fr) 2013-03-14 2017-06-07 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
CA2903264A1 (fr) 2013-03-14 2014-11-06 Epizyme, Inc. Inhibiteurs de l'arginine methyltransferase et utilisations de ceux-ci
EP2970135B1 (fr) 2013-03-14 2018-07-18 Epizyme, Inc. Derives de pyrazol comme des inhibiteurs de prmt1 et leur utilisation
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3417858B8 (fr) 2016-02-19 2020-12-30 National University Corporation Tottori University Médicament thérapeutique ou prophylactique pour la démence
ITUA20164199A1 (it) 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Modulatori di soce compisizioni e relativi usi
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
CA2409819C (fr) * 2000-05-19 2009-09-15 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
DE10149370A1 (de) 2003-04-10
WO2003031435A1 (fr) 2003-04-17
AU2002342675A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2003031435A8 (fr) Derives pyrazole inhibiteurs de transport de glycine
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
WO2002085909A8 (fr) Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
WO2002098849A3 (fr) Hydroxyalkylamines
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
ATE248837T1 (de) Chinuclidin-acrylamide
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
SG148846A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimeræs and related neurodegenerative disorders
SE0104332D0 (sv) Therapeutic agents
GEP20063958B (en) 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2005018557A3 (fr) Pyridinones substitues
ATE495741T1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
YU29102A (sh) Heteroalkilamino-supstituisani biciklični azotni heterocikli kao inhibitori p38 protein kinaze
GEP20125405B (en) Amino-heterocyclic compounds
NO20025517D0 (no) Triazolderivater
WO2005065195A3 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
WO2005111002A3 (fr) Derives de cycloalkyle substitues, leur procede de production et leur utilisation comme medicaments
MXPA05014201A (es) Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3.
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
AU2001241183A1 (en) Amide compounds and use thereof
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
AR028705A1 (es) Bis-arilsulfonas
WO2003087049A3 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP